Literature DB >> 25917533

Clostridium Difficile Infection from a Surgical Perspective.

Andreas M Kaiser1, Rachel Hogen, Liliana Bordeianou, Karim Alavi, Paul E Wise, Ranjan Sudan.   

Abstract

BACKGROUND: The incidence and the severity of Clostridium difficile infection (CDI) have increased significantly over the last decade, especially in high-risk populations such as patients with inflammatory bowel disease (IBD). Surgeons must be able to both identify and minimize the risk of CDI in their own surgical patients and determine which CDI patients will benefit from surgery.
PURPOSE: We sought to define the risk factors, compare the treatment options, define the surgical indications, and identify factors that affect surgical outcomes for CDI based on the currently available literature.
RESULTS: Antibiotic use, exposure to the C. difficile bacteria, IBD, and higher levels of co-morbidity are all risk factors for CDI. The majority of CDI can be treated with antibiotics. Severe or fulminant colitis, however, has a high potential for poor outcome, but experience and some data suggest a lower mortality rate with colectomy rather than with continued medical treatment. Open total abdominal colectomy with end ileostomy is typically the preferred surgical strategy. It is often difficult to determine which patients will fail medical management as some may not manifest clinical signs of severe infection. Surrogate parameters of failure of medical therapy include respiratory and/or renal insufficiency, age greater than 60 years, peripheral vascular disease, congestive heart failure, and coagulopathy, all of which have been associated with worse surgical outcomes. Evidence suggests that in appropriately selected patients, colectomy performed before the development of shock requiring vasopressors, respiratory failure, renal failure, multi-organ dysfunction, and mental status changes may reduce mortality of the most severe forms of colitis. For less severe or recurrent presentations, creation of a loop ileostomy with intra-operative colonic lavage, fecal microbiota transfer, and C. difficile vaccinations are being discussed but have only been studied in small case-controlled series.
CONCLUSIONS: Prevention, containment, and non-surgical treatment are the cornerstone of management for CDI. However, the most severe forms with toxic colitis benefit from involvement of a surgical team. Swift open total abdominal colectomy with end ileostomy in patients with severe or fulminant C. difficile colitis has the best chance to reduce mortality if it is not delayed until shock, end organ damage, vasopressor requirement, mental status changes develop. Less aggressive approaches may be appropriate for milder and refractory forms but require further study before their applicability can be determined.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917533     DOI: 10.1007/s11605-015-2785-4

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  108 in total

1.  Preventing Clostridium difficile infections: an executive summary of the Association for Professionals in Infection Control and Epidemiology's elimination guide.

Authors:  Terri Rebmann; Ruth M Carrico
Journal:  Am J Infect Control       Date:  2011-03-03       Impact factor: 2.918

Review 2.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

3.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

4.  Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans.

Authors:  Anna M Buchner; Amnon Sonnenberg
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

5.  Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases.

Authors:  Rocco Ricciardi; James W Ogilvie; Patricia L Roberts; Peter W Marcello; Thomas W Concannon; Nancy N Baxter
Journal:  Dis Colon Rectum       Date:  2009-01       Impact factor: 4.585

Review 6.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI).

Authors:  M J T Crobach; O M Dekkers; M H Wilcox; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

7.  PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics.

Authors:  Alizah Rotramel; Lisa S Poritz; Evangelos Messaris; Arthur Berg; David B Stewart
Journal:  J Gastrointest Surg       Date:  2012-09-25       Impact factor: 3.452

Review 8.  Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.

Authors:  Joshua Z Goldenberg; Stephanie S Y Ma; Jane D Saxton; Mark R Martzen; Per O Vandvik; Kristian Thorlund; Gordon H Guyatt; Bradley C Johnston
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

9.  Effect on diagnostic yield of repeated stool testing during outbreaks of Clostridium difficile-associated disease.

Authors:  S B Debast; E van Kregten; K M G Oskam; T van den Berg; R J Van den Berg; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2008-04-03       Impact factor: 8.067

10.  Clostridium difficile skin contamination in patients with C. difficile-associated disease.

Authors:  Greg S Bobulsky; Wafa N Al-Nassir; Michelle M Riggs; Ajay K Sethi; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

View more
  3 in total

Review 1.  2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients.

Authors:  Massimo Sartelli; Stefano Di Bella; Lynne V McFarland; Sahil Khanna; Luis Furuya-Kanamori; Nadir Abuzeid; Fikri M Abu-Zidan; Luca Ansaloni; Goran Augustin; Miklosh Bala; Offir Ben-Ishay; Walter L Biffl; Stephen M Brecher; Adrián Camacho-Ortiz; Miguel A Caínzos; Shirley Chan; Jill R Cherry-Bukowiec; Jesse Clanton; Federico Coccolini; Maria E Cocuz; Raul Coimbra; Francesco Cortese; Yunfeng Cui; Jacek Czepiel; Zaza Demetrashvili; Isidoro Di Carlo; Salomone Di Saverio; Irina M Dumitru; Christian Eckmann; Edward H Eiland; Joseph D Forrester; Gustavo P Fraga; Jean L Frossard; Donald E Fry; Rita Galeiras; Wagih Ghnnam; Carlos A Gomes; Ewen A Griffiths; Xavier Guirao; Mohamed H Ahmed; Torsten Herzog; Jae Il Kim; Tariq Iqbal; Arda Isik; Kamal M F Itani; Francesco M Labricciosa; Yeong Y Lee; Paul Juang; Aleksandar Karamarkovic; Peter K Kim; Yoram Kluger; Ari Leppaniemi; Varut Lohsiriwat; Gustavo M Machain; Sanjay Marwah; John E Mazuski; Gokhan Metan; Ernest E Moore; Frederick A Moore; Carlos A Ordoñez; Leonardo Pagani; Nicola Petrosillo; Francisco Portela; Kemal Rasa; Miran Rems; Boris E Sakakushev; Helmut Segovia-Lohse; Gabriele Sganga; Vishal G Shelat; Patrizia Spigaglia; Pierre Tattevin; Cristian Tranà; Libor Urbánek; Jan Ulrych; Pierluigi Viale; Gian L Baiocchi; Fausto Catena
Journal:  World J Emerg Surg       Date:  2019-02-28       Impact factor: 5.469

2.  Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice.

Authors:  Jiani Wang; Christina Ortiz; Lindsey Fontenot; Riya Mukhopadhyay; Ying Xie; Xinhua Chen; Hanping Feng; Charalabos Pothoulakis; Hon Wai Koon
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 7.759

Review 3.  Systems Biology Approaches for Therapeutics Development Against COVID-19.

Authors:  Shweta Jaiswal; Mohit Kumar; Yogendra Singh; Pratyoosh Shukla
Journal:  Front Cell Infect Microbiol       Date:  2020-10-28       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.